IL17A and psoriasis: This NMA includes the newly licensed anti-IL-17A monoclonal antibody, ixekizumab, and considers joint rankings of multiple outcomes for psoriasis, including DLQI, and to provide absolute effect estimates to help inform clinical decision making.